The FDA uses three principal pre-market review pathways for medical devices: 510(k) clearance, Premarket Approval (PMA), and De Novo classification. Choosing the right pathway — or understanding which pathway a competitor used — is fundamental to evaluating a medical device company’s US market status. For surgical robots, the choice has major implications for clinical evidence requirements, timeline, and what post-approval changes are permitted.
Device Classification Drives Pathway
Before selecting a submission type, a manufacturer must determine device classification. FDA classifies medical devices into three classes:
- Class I — general controls sufficient for safety (e.g., bandages, tongue depressors). Most are exempt from pre-market review.
- Class II — general controls plus special controls; most require 510(k) clearance.
- Class III — highest risk; requires either PMA or, if a new device type without a predicate, De Novo followed by potential 510(k) for future predicates.
Surgical robots are generally Class II or Class III depending on their intended use and degree of autonomy. A robot that assists a surgeon who retains full control differs regulatorily from a device with autonomous cutting capability.
The 510(k) Pathway
The 510(k) — named for the section of the Food, Drug, and Cosmetic Act — is a notification that a device is substantially equivalent to a legally marketed predicate device. It is not an “approval”; FDA issues a clearance letter.
Core argument: The new device has the same intended use as the predicate and the same or different technological characteristics, and any different technological characteristics do not raise new safety or efficacy questions.
What 510(k) does not require: An independent clinical trial demonstrating safety and efficacy. Literature reviews, bench testing, and performance data typically suffice if the substantial equivalence argument holds.
Timeline: FDA’s performance goal under MDUFA V is to review 90% of 510(k) submissions within 90 days of acceptance. Total elapsed time including FDA hold periods and company response time varies but commonly runs 6–12 months.
Post-clearance changes: Significant design changes require a new 510(k). Minor changes may be documented internally under a change control procedure. The line between “significant” and “minor” is defined in FDA guidance but requires manufacturer judgment.
Many laparoscopic surgical robotic platforms have obtained 510(k) clearance. R-One from Robocath is an example in the vascular space where substantial equivalence to predicate catheter navigation systems supported the 510(k) route.
The PMA Pathway
Premarket Approval applies to Class III devices that support or sustain life, are implanted, or present unreasonable risk of illness or injury such that general and special controls alone cannot provide reasonable assurance of safety and efficacy.
Core requirement: Valid scientific evidence — typically including at least one well-controlled clinical investigation — that the device is safe and effective for its intended use.
What PMA requires: A complete PMA application includes device description, manufacturing information, performance testing, risk analysis, and clinical data from human studies. FDA’s review involves a primary review, often a panel advisory meeting with external clinical experts, and may involve multiple review cycles.
Timeline: FDA’s MDUFA V performance goal is 180 days for original PMAs. Total elapsed time including clinical trials and review cycles commonly runs several years from initial clinical study design to final approval.
Post-approval changes: Significant changes require a PMA supplement, which can take months to years depending on supplement type. Some changes qualify for a 30-day notice rather than a full supplement.
The da Vinci robotic surgical system (Intuitive Surgical) holds several PMA approvals for high-risk indications. Intuitive-Fosun, the joint venture distributing da Vinci systems in China, operates under both FDA PMAs for the US market and NMPA Class III registrations for China.
The De Novo Pathway
De Novo is the pathway for novel, low-to-moderate-risk devices that lack a valid predicate for 510(k) but do not warrant Class III PMA classification. It creates a new device type, which then can serve as a predicate for future 510(k)s.
When it applies: When a manufacturer has a genuinely novel device that FDA has not previously classified, and the manufacturer believes Class III is too burdensome given the device’s actual risk profile. A De Novo request asks FDA to review the device and establish a new classification with appropriate special controls.
What De Novo requires: Performance data, special controls proposed by the manufacturer, and often an FDA meeting to discuss the classification rationale. Clinical data may or may not be required depending on device type.
Timeline: FDA’s MDUFA V goal for De Novo requests is 150 days. Total elapsed time varies.
Post-De Novo: Once FDA grants De Novo, the device is classified Class II. It becomes a predicate — subsequent manufacturers with similar devices can submit 510(k)s referencing it. This has strategic importance: being the company that created the device type gives a first-mover advantage in the predicate landscape.
Several robotic navigation and soft-tissue robotic assistance devices have pursued De Novo when their technology was novel but their risk profile did not warrant full PMA.
Pathway Selection Summary
| Factor | 510(k) | De Novo | PMA |
|---|---|---|---|
| Device class | Class I/II | Class II (novel type) | Class III |
| Predicate required | Yes | No | No |
| Clinical trial typically required | No | Sometimes | Yes |
| FDA performance goal | 90 days | 150 days | 180 days |
| Post-clearance change flexibility | Moderate | Moderate | Lower |
Implications for Chinese Robot Manufacturers Entering the US
Chinese manufacturers pursuing FDA clearance or approval face the same technical requirements as domestic US manufacturers. Several strategic considerations apply:
Predicate selection for 510(k): The predicate device must be legally marketed (cleared or approved) in the US. A Chinese device that received NMPA approval does not constitute a US predicate. Manufacturers must identify an appropriate US-cleared device with matching intended use and comparable technology.
Clinical data from Chinese trials: FDA may accept foreign clinical data under 21 CFR 312.120 if it meets FDA standards for good clinical practice and the data are applicable to the US population and practice. However, FDA retains discretion to require additional US studies, particularly for novel robotic devices where practice patterns differ.
Quality system: PMA and 510(k) applicants must demonstrate compliance with FDA’s Quality System Regulation (21 CFR Part 820) or its successor framework. Manufacturing in China is subject to FDA inspection, including for-cause inspections.
Frequently Asked Questions
Is 510(k) clearance the same as FDA approval?
No. 510(k) is a clearance based on substantial equivalence to a predicate. PMA is an approval based on independent evidence of safety and efficacy. Marketing materials for 510(k)-cleared devices should not say “FDA approved.”
Can a Class III device use 510(k)?
No. Class III devices require PMA or, if reclassified, De Novo. However, a device may enter the market as Class III under a PMA and later be reclassified to Class II through a petition process, enabling future 510(k)s for equivalent devices.
What is a “predicate device” and how does a manufacturer find one?
A predicate is a device already legally marketed in the US with the same or substantially similar intended use. Manufacturers search FDA’s 510(k) database and PMA database to identify potential predicates. The choice of predicate affects which performance standards and special controls apply.
How long does total 510(k) clearance take in practice?
FDA’s 90-day performance goal measures from acceptance, not from submission. Hold periods (when FDA puts the review on hold pending manufacturer response) pause the clock but add real time. Total elapsed time from submission to clearance commonly ranges from 6 months to over a year, depending on deficiencies.
Does a De Novo decision have to be renewed?
No. A De Novo classification decision creates a permanent device classification. The device retains Class II status and can be marketed indefinitely as long as the manufacturer maintains quality system compliance and meets post-market requirements. There is no expiration date on the classification.